Drug intelligence / Profile preview

eutideron

Development stage: Unknown
Lead developer: Beijing Biostar Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous

Overview

Eutideron is a new generation of epirubicin anti-tumor drug with good efficacy and safety. In pre-clinical studies, it has been shown to achieve higher concentrations in brain tissue than in plasma, indicating it can cross the blood-brain barrier. It is being studied in combination with etoposide and bevacizumab for the treatment of brain metastases from breast cancer.

Other names: eutiderone

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on eutideron.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eutideron.

Explore the full profile